Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.39
-0.0200-1.42%
Pre-market: 1.39-0.0011-0.08%07:42 EDT
Volume:558.01K
Turnover:786.41K
Market Cap:84.33M
PE:-2.28
High:1.47
Open:1.41
Low:1.39
Close:1.41
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.61M
Volume Ratio:1.32
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:4.08
PE(LYR):-1.99

Loading ...

Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
May 15

Maia Biotechnology Inc - to Terminate at the Market Offering Agreement Effective May 23, 2026 - SEC Filing

THOMSON REUTERS
·
May 15

MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate

Benzinga Earnings
·
May 11

Maia Biotechnology Q1 net loss widens 41% to $6.37 million

Reuters
·
May 11

Maia Biotech opens first US site for Phase 2 THIO-101 lung cancer trial

Reuters
·
Apr 16

MAIA Biotechnology secures funding for clinical trial of ateganosine

TIPRANKS
·
Apr 08

Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial

Reuters
·
Apr 08

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

GlobeNewswire
·
Apr 08

Maia Biotechnology announces annual shareholder meeting in virtual format

Reuters
·
Apr 07

MAIA Biotechnology Awards Executive Bonuses After Successful Financing

TIPRANKS
·
Apr 03

Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise

Reuters
·
Apr 03

MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes

TIPRANKS
·
Apr 01

BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer

Reuters
·
Mar 31

MAIA Showcases THIO-101 NSCLC Data at ELCC 2026

TIPRANKS
·
Mar 27

MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate

Benzinga Earnings
·
Mar 24

Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million

Reuters
·
Mar 23

MAIA Biotechnology Completes $30 Million Public Stock Offering

TIPRANKS
·
Mar 05

BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing

Reuters
·
Mar 05

Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing

THOMSON REUTERS
·
Mar 05

Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 05